Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP6294 for bladder pain syndrome/interstitial cystitis in adult women
NL-OMON45673Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2018
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) comparing ASP6294 with Placebo (2 arms). Primary endpoint: Change from baseline in average MDP at Week 12. Started Apr 2018; status: completed.
02
Drugs
ASP6294
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on NL-OMON45673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45673.